Case 1:22-cv-00252-MSG Document 133-1 Filed 09/27/23 Page 1 of 8 PageID #: 1765
`
`Exhibit A
`
`
`
`
`
`
`
`
`
`

`

`Plaintiffs,
`
`
`
`v.
`
`ARBUTUS BIOPHARMA CORPORATION
`and GENEVANT SCIENCES GmbH,
`
`
`
`
`
`MODERNA, INC. and MODERNATX, INC.
`
`Defendants.
`
`
`MODERNA, INC. and MODERNATX, INC.,
`
`
`Counterclaim-Plaintiffs,
`
`
`
`v.
`
`
`ARBUTUS BIOPHARMA CORPORATION
`and GENEVANT SCIENCES GmbH,
`
`
`Counterclaim-Defendants.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Case 1:22-cv-00252-MSG Document 133-1 Filed 09/27/23 Page 2 of 8 PageID #: 1766
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`
`
`
`C.A. No. 22-252 (MSG)
`
`
`HIGHLY CONFIDENTIAL –
`OUTSIDE COUNSEL’S EYES ONLY
`
`JURY TRIAL DEMANDED
`
`
`
`
`
`DEFENDANTS’ RESPONSES AND OBJECTIONS TO PLAINTIFFS’ SECOND SET OF
`REQUESTS FOR PRODUCTION TO DEFENDANTS (NOS. 99–127)
`
`Pursuant to Federal Rules of Civil Procedure 26 and 34, Defendants Moderna, Inc. and
`
`ModernaTX, Inc. (collectively, “Moderna” or “Defendants”) provide their responses and
`
`objections to Plaintiffs Arbutus Biopharma Corporation (“Arbutus”) and Genevant Sciences
`
`GmbH (“Genevant”)’s requests for production.
`
`GENERAL OBJECTIONS
`
`Moderna incorporates by reference its General Objections provided in Moderna’s
`
`Responses and Objections to Plaintiffs’ First Set of Requests for Production to Defendants (Nos.
`
`1–98) served February 2, 2023.
`
`
`
`

`

`Case 1:22-cv-00252-MSG Document 133-1 Filed 09/27/23 Page 3 of 8 PageID #: 1767
`HIGHLY CONFIDENTIAL – OUTSIDE COUNSEL’S EYES ONLY
`
`DEFINITIONS
`
`Moderna incorporates by reference the Definitions provided in Moderna’s Responses and
`
`Objections to Plaintiffs’ First Set of Requests for Production to Defendants (Nos. 1–98) served
`
`February 2, 2023.
`
`OBJECTIONS TO REQUESTS FOR PRODUCTION
`
`REQUEST FOR PRODUCTION NO. 99:
`
`All documents and communications by, with, or from Stéphane Bancel related to the
`Accused Product, the Patents-in-Suit, Plaintiffs, Operation Warp Speed, Contract No. W911QY-
`20-C-0100, or Contract No. W58P05-22-C-0017.
`
`RESPONSE TO REQUEST FOR PRODUCTION NO. 99:
`
`Moderna objects to this Request as overbroad, unduly burdensome, and calling for
`
`information not relevant to any of the claims or defenses in this litigation and/or not proportional
`
`to the needs of this case, including because it seeks “[a]ll documents and communications by, with,
`
`or from Stéphane Bancel” related to various overbroad topics including the Accused Product and
`
`Operation Warp Speed, Contract No. W911QY-20-C-0100, or Contract No. W58P05-22-C-0017,
`
`which presumes that all such documents and communications are relevant. Moderna will not
`
`produce irrelevant and/or non-responsive documents. Moderna objects to this Request as
`
`overbroad, unduly burdensome, and calling for information not relevant to any of the claims or
`
`defenses in this litigation and/or not proportional to the needs of this case, specifically because it
`
`lacks reasonable temporal restrictions. Moderna objects to this Request as seeking the production
`
`of documents protected from discovery by the attorney-client privilege, the work-product doctrine,
`
`or any other applicable privilege or immunity. Moderna will not produce such documents.
`
`Moderna objects to this Request as improperly seeking to expand upon the default number of ESI
`
`custodians under the Delaware Default Standard. Moderna has already identified a proportional
`
`number of ESI custodians most likely to have relevant ESI, including custodians with information
`
`2
`
`

`

`Case 1:22-cv-00252-MSG Document 133-1 Filed 09/27/23 Page 4 of 8 PageID #: 1768
`HIGHLY CONFIDENTIAL – OUTSIDE COUNSEL’S EYES ONLY
`
`concerning the C-0100 and C-0017 contracts. Moderna objects to this Request to the extent it seeks
`
`documents that are protected by confidentiality obligations to third parties that prohibit or restrict
`
`their disclosure by Moderna (by agreement or by law) and will not produce such documents.
`
`Moderna objects to this Request as duplicative of at least RFP Nos. 6, 47, 49, and 50. Moderna
`
`also objects to this Request to the extent it calls for information that is publicly available. Moderna
`
`will not search for and produce information that is publicly available.
`
`Subject to and without waiving any of its general or specific objections, Moderna will not
`
`produce documents solely in response to this Request.
`
`REQUEST FOR PRODUCTION NO. 100:
`
`All documents and communications by, with, or from Moncef Slaoui related to the Accused
`Product, the Patents-in-Suit, Plaintiffs, Operation Warp Speed, Contract No. W911QY-20-C-
`0100, or Contract No. W58P05-22-C-0017.
`
`RESPONSE TO REQUEST FOR PRODUCTION NO. 100:
`
`Moderna objects to this Request as overbroad, unduly burdensome, and calling for
`
`information not relevant to any of the claims or defenses in this litigation and/or not proportional
`
`to the needs of this case, including because it seeks “[a]ll documents and communications by, with,
`
`or from Moncef Slaoui” related to various overbroad topics including the Accused Product and
`
`Operation Warp Speed, Contract No. W911QY-20-C-0100, or Contract No. W58P05-22-C-0017,
`
`which presumes that all such documents and communications are relevant. Moderna will not
`
`produce irrelevant and/or non-responsive documents. Moderna objects to this Request as
`
`overbroad, unduly burdensome, and calling for information not relevant to any of the claims or
`
`defenses in this litigation and/or not proportional to the needs of this case, specifically because it
`
`lacks reasonable temporal restrictions. Moderna objects to this Request as seeking the production
`
`of documents protected from discovery by the attorney-client privilege, the work-product doctrine,
`
`3
`
`

`

`Case 1:22-cv-00252-MSG Document 133-1 Filed 09/27/23 Page 5 of 8 PageID #: 1769
`HIGHLY CONFIDENTIAL – OUTSIDE COUNSEL’S EYES ONLY
`
`REQUEST FOR PRODUCTION NO. 118:
`
`All documents produced by Moderna related to the Accused Product in ModernaTX, Inc.
`and Moderna US, Inc. v. Pfizer Inc., BioNTech SE, BioNTech Manufacturing GmbH, and
`BioNTech US Inc., Case 1:22-cv-11378-RGS (D. Mass.).
`
`RESPONSE TO REQUEST FOR PRODUCTION NO. 118:
`
`Moderna objects to this Request as overbroad, unduly burdensome, and calling for
`
`information not relevant to any of the claims or defenses in this litigation and/or not proportional
`
`to the needs of this case, including because it seeks “[a]ll documents produced by Moderna related
`
`to the Accused Product” in Moderna v. Pfizer litigation (C.A. No. 22-cv-11378 (D. Mass.)), which
`
`involves different patents from the current case, and potentially encompasses an enormous volume
`
`of documents, not all of which will have relevance to the issues in dispute, and some of which may
`
`require redaction and/or review for third-party confidentiality. Moderna will not produce irrelevant
`
`and/or non-responsive documents, including documents relating to aspects of the Accused
`
`Products that are not relevant to the Asserted Claims. Moderna objects to this Request to the extent
`
`it seeks proprietary, confidential, or trade secret information of Moderna or of others to whom
`
`Moderna is under an obligation of confidentiality (by agreement or by law).
`
`Subject to and without waiving any of its general or specific objections, Moderna is willing
`
`to meet and confer regarding this Request.
`
`REQUEST FOR PRODUCTION NO. 119:
`
`All pleadings, correspondence, transcripts, discovery requests, discovery responses, or
`other documents associated with ModernaTX, Inc. and Moderna US, Inc. v. Pfizer Inc., BioNTech
`SE, BioNTech Manufacturing GmbH, and BioNTech US Inc., Case 1:22-cv-11378-RGS (D.
`Mass.), including but not limited to requests for production, responses to requests for production,
`interrogatories, interrogatory responses, discovery correspondence, briefs, deposition transcripts,
`and hearing transcripts.
`
`24
`
`

`

`Case 1:22-cv-00252-MSG Document 133-1 Filed 09/27/23 Page 6 of 8 PageID #: 1770
`HIGHLY CONFIDENTIAL – OUTSIDE COUNSEL’S EYES ONLY
`
`
`
`
`
`
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`/s/ Brian P. Egan
`
`
`
`
`Jack B. Blumenfeld (#1014)
`Brian P. Egan (#6227)
`Travis J. Murray (#6882)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@morrisnichols.com
`began@morrisnichols.com
`tmurray@morrisnichols.com
`
`Attorneys for Defendants
`
`
`
`
`
`
`OF COUNSEL:
`
`James F. Hurst
`KIRKLAND & ELLIS LLP
`300 North LaSalle
`Chicago, IL 60654
`(312) 862-2000
`
`Patricia A. Carson, Ph.D.
`Jeanna M. Wacker, P.C.
`Mark C. McLennan
`Nancy Kaye Horstman
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue
`New York, NY 10022
`(212) 446-4800
`
`Yan-Xin Li
`KIRKLAND & ELLIS LLP
`555 California Street, 27th Floor
`San Francisco, CA 94104
`(415) 439-1400
`
`Alina Afinogenova
`KIRKLAND & ELLIS LLP
`200 Clarendon Street
`Boston, MA 02116
`(617) 385-7500
`
`June 26, 2023
`
`34
`
`

`

`Case 1:22-cv-00252-MSG Document 133-1 Filed 09/27/23 Page 7 of 8 PageID #: 1771
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on June 26, 2023, copies of the foregoing were caused to be served
`
`VIA ELECTRONIC MAIL
`
`VIA ELECTRONIC MAIL
`
`VIA ELECTRONIC MAIL
`
`VIA ELECTRONIC MAIL
`
`upon the following in the manner indicated:
`
`John W. Shaw, Esquire
`Karen E. Keller, Esquire
`Nathan R. Hoeschen, Esquire
`Emily S. DiBenedetto, Esquire
`SHAW KELLER LLP
`I.M. Pei Building
`1105 North Market Street, 12th Floor
`Wilmington, DE 19801
`Attorneys for Plaintiffs Arbutus Biopharma
`Corporation and Genevant Sciences GmbH
`
`Daralyn J. Durie, Esquire
`Adam R. Brausa, Esquire
`Annie A. Lee, Esquire
`Shaelyn K. Dawson, Esquire
`MORRISON & FOERSTER LLP
`425 Market Street
`San Francisco, CA 94105-2482
`Attorneys for Plaintiff Arbutus Biopharma
`Corporation
`
`Kira A. Davis, Esquire
`MORRISON & FOERSTER LLP
`707 Wilshire Boulevard
`Los Angeles, CA 90017-3543
`Attorneys for Plaintiff Arbutus Biopharma
`Corporation
`
`David N. Tan, Esquire
`MORRISON & FOERSTER LLP
`2100 L Street, NW, Suite 900
`Washington, DC 20037
`Attorneys for Plaintiff Arbutus Biopharma
`Corporation
`
`
`
`
`

`

`Case 1:22-cv-00252-MSG Document 133-1 Filed 09/27/23 Page 8 of 8 PageID #: 1772
`
`
`David I. Berl, Esquire
`Adam D. Harber, Esquire
`Thomas S. Fletcher, Esquire
`Jessica Palmer Ryen, Esquire
`Lydia B. Cash, Esquire
`Shaun P. Mahaffy, Esquire
`Anthony H. Sheh, Esquire
`Philip N. Haunschild, Esquire
`Jihad J. Komis, Esquire
`WILLIAMS & CONNOLLY LLP
`680 Maine Avenue S.W.
`Washington, DC 20024
`Attorneys for Plaintiff Genevant Sciences
`GmbH
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`VIA ELECTRONIC MAIL
`
`/s/ Brian P. Egan
`
`
`
`
`Brian P. Egan (#6227)
`
`
`
`
`
`
`
`
`
`
`
`
`36
`
`